Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.79
ALIM's Cash-to-Debt is ranked lower than
65% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. ALIM: 0.79 )
Ranked among companies with meaningful Cash-to-Debt only.
ALIM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 5.37 Max: N/A
Current: 0.79
Equity-to-Asset 0.32
ALIM's Equity-to-Asset is ranked lower than
84% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. ALIM: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
ALIM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.25  Med: 0.31 Max: 0.46
Current: 0.32
-0.25
0.46
Piotroski F-Score: 4
Altman Z-Score: -7.28
Beneish M-Score: -2.79
WACC vs ROIC
18.14%
-86.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -69.89
ALIM's Operating Margin % is ranked lower than
85% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. ALIM: -69.89 )
Ranked among companies with meaningful Operating Margin % only.
ALIM' s Operating Margin % Range Over the Past 10 Years
Min: -1837.82  Med: -282.49 Max: -81.11
Current: -69.89
-1837.82
-81.11
Net Margin % -81.83
ALIM's Net Margin % is ranked lower than
86% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. ALIM: -81.83 )
Ranked among companies with meaningful Net Margin % only.
ALIM' s Net Margin % Range Over the Past 10 Years
Min: -2469.5  Med: -281.46 Max: -96.62
Current: -81.83
-2469.5
-96.62
ROE % -137.79
ALIM's ROE % is ranked lower than
94% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. ALIM: -137.79 )
Ranked among companies with meaningful ROE % only.
ALIM' s ROE % Range Over the Past 10 Years
Min: -299.13  Med: -104.32 Max: -61.59
Current: -137.79
-299.13
-61.59
ROA % -43.77
ALIM's ROA % is ranked lower than
89% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. ALIM: -43.77 )
Ranked among companies with meaningful ROA % only.
ALIM' s ROA % Range Over the Past 10 Years
Min: -329.68  Med: -48.29 Max: -20.46
Current: -43.77
-329.68
-20.46
ROC (Joel Greenblatt) % -263.60
ALIM's ROC (Joel Greenblatt) % is ranked lower than
86% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. ALIM: -263.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALIM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12190.35  Med: -3400.49 Max: -309.12
Current: -263.6
-12190.35
-309.12
3-Year Revenue Growth Rate 122.50
ALIM's 3-Year Revenue Growth Rate is ranked higher than
99% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. ALIM: 122.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALIM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 122.5
Current: 122.5
0
122.5
3-Year EBITDA Growth Rate -24.10
ALIM's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. ALIM: -24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALIM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -43.6 Max: 11
Current: -24.1
0
11
3-Year EPS without NRI Growth Rate -27.00
ALIM's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. ALIM: -27.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALIM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.35 Max: 19.6
Current: -27
0
19.6
GuruFocus has detected 1 Warning Sign with Alimera Sciences Inc $ALIM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALIM's 30-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ALIM Guru Trades in Q4 2015

Jim Simons 75,200 sh (-40.86%)
» More
Q1 2016

ALIM Guru Trades in Q1 2016

Jim Simons Sold Out
» More
Q4 2016

ALIM Guru Trades in Q4 2016

Jim Simons 59,600 sh (New)
» More
Q1 2017

ALIM Guru Trades in Q1 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ALIM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:AMEX:NNVC, OTCPK:MBGRF, NAS:OASM, NAS:TNXP, NAS:PRPH, AMEX:AXN, NAS:IMNP, OTCPK:CHEXD, OTCPK:SUWN, OTCPK:INNV, NAS:ALQA, NAS:NVGN, AMEX:CPHI, NAS:BSPM, OTCPK:ATHJF, OTCPK:INBP, OTCPK:ECTE, NAS:NBRV, NAS:ZGNX, NAS:RMTI » details
Traded in other countries:ASZ.Germany,
Headquarter Location:USA
Alimera Sciences Inc is a pharmaceutical company. The Company, along with its subsidiaries is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

Alimera Sciences is a biopharmaceutical company engaged in the research, development, and commercialization of ophthalmic pharmaceuticals. The company presently focuses on diseases affecting the back of the eye, or retina, and looks to improve upon current therapies with its pipeline drug candidates.

Top Ranked Articles about Alimera Sciences Inc

Alimera Sciences Reports First Quarter 2017 Financial Results
Alimera Sciences to Report First Quarter 2017 Financial Results on May 8th, 2017
Alimera Sciences Announces Data From 27 ILUVIEN® Studies to Be Presented at 2017 ARVO
Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain

Brill Pharma S.L. to also serve as agent in price negotiations
with the Spanish Ministry of Health ATLANTA, March 13, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Alimera Sciences Limited, its European subsidiary based in London, has signed an exclusive agreement with Brill Pharma S. L. (Brill Pharma), Barcelona, Spain, for distribution of ILUVIEN® in the Kingdom of Spain, Alimera's sustained release intravitreal injection for the treatment of diabetic macular edema. Under the terms of this agreement, Brill Pharma will handle promotion, marketing and commercial activities in Spain for ILUVIEN. In addition, Brill will negotiate with the Spanish Ministry of Health on the appropriate confidential net price for reimbursement of ILUVIEN within the Spanish National Health System, as well as on the public price. “As a continuous microdosing treatment that lasts for up to three years, ILUVIEN can make a major difference to patients with DME in Spain,” said Dan Myers, President and Chief Executive Officer of Alimera. “With the help of Brill Pharma's experienced team, we expect to reach Spanish patients and their physicians with a truly innovative product that can consistently treat their disease every day and markedly improve their quality of life.”  “Spain has a strong tradition in the use of corticosteroids being one of the largest markets in Europe. The introduction of ILUVIEN will represent a substantial improvement in the long term management of the pathology and the quality of life of a significant number of patients. Brill Pharma will be the first pharmaceutical company with Spanish capital, marketing an innovative intravitreal product in diabetic macular edema,” said Dr. Jordi Martinez Rotllan, Chief Executive Officer of Brill Pharma. About ILUVIEN www.ILUVIEN.com. ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant indicated in the E.U. to treat vision impairment associated with chronic DME considered insufficiently responsive to available therapies. Each ILUVIEN implant with its continuous microdosing is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months, enabling the physician to treat the disease consistently every day. About Diabetic Macular Edema (DME) DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME. About Alimera Sciences, Inc. www.alimerasciences.com Alimera, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com. About Brill Pharma S. L. Brill Pharma, the Spanish subsidiary of Bristol Laboratories U.K., is based in Barcelona, Spain and was established in September 2012. It markets innovative products in ophthalmology, is already ranked fourth in this specific segment of the Spanish pharma market and was recently recognized as the fastest growing Spanish pharma company in its segment. The company employs more than 60 medical representatives covering Spain. For further details, please visit www.brillpharma.com. Forward Looking Statements This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, that Alimera believes it will reach Spanish patients and physicians with Brill Pharma’s team. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, Brill Pharma’s ability to launch ILUVIEN in 2017 in Spain, Brill Pharma’s ability to successfully negotiate a price for ILUVIEN with the Spanish Ministry of Health, Brill Pharma’s ability to provide adequate promotion, marketing and commercial support for ILUVIEN, physician’s in Spain will acceptance ILUVIEN for use with their DME patients, and ILUVIEN acceptance by various institutions in the Spain, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov.  In addition to the risks described above and in Alimera’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For press inquiries:
Katie Brazel
for Alimera Sciences
404-317-8361
[email protected]

For investor inquiries:
CG Capital
for Alimera Sciences
877-889-1972
[email protected]

Read more...
Alimera Sciences to Present at the 29th Annual ROTH Conference

ATLANTA, March 07, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization, research and development of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the 29th Annual ROTH Conference, to be held March 12-15, 2017 at the Ritz Carlton, Orange County, CA. The Company's presentation will take place Wednesday, March 15, 2017, at 10:00 AM Pacific Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimerasciences.com. A replay of the conference presentation will also be available. About Alimera Sciences Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization, research and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com. Contact: CG CAPITAL 877.889.1972 [email protected] cg.capital


Read more...
Alimera Sciences to Present at the 37th Annual Cowen Health Care Conference

ATLANTA, March 03, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization, research and development of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the 37th Annual Cowen Health Care Conference, to be held March 6-8, 2017 at The Boston Marriott Copley Place, Boston, Massachusetts. Alimera Sciences' presentation will take place Monday, March 6, 2017, at 4:40 PM Eastern Time. A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimeraciences.com. A replay of the conference presentation will also be available. About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization, research and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact:
CG Capital
877.889.1972
[email protected]
cg.capital

Read more...

Ratios

vs
industry
vs
history
PS Ratio 2.32
ALIM's PS Ratio is ranked higher than
63% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. ALIM: 2.32 )
Ranked among companies with meaningful PS Ratio only.
ALIM' s PS Ratio Range Over the Past 10 Years
Min: 1.64  Med: 16.71 Max: 853.33
Current: 2.32
1.64
853.33
EV-to-EBIT -6.92
ALIM's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. ALIM: -6.92 )
Ranked among companies with meaningful EV-to-EBIT only.
ALIM' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.7  Med: -5.3 Max: -2
Current: -6.92
-8.7
-2
EV-to-EBITDA -7.79
ALIM's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. ALIM: -7.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALIM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.9  Med: -5.7 Max: -2
Current: -7.79
-8.9
-2
Current Ratio 5.97
ALIM's Current Ratio is ranked higher than
77% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. ALIM: 5.97 )
Ranked among companies with meaningful Current Ratio only.
ALIM' s Current Ratio Range Over the Past 10 Years
Min: 0.59  Med: 5.2 Max: 11.78
Current: 5.97
0.59
11.78
Quick Ratio 5.85
ALIM's Quick Ratio is ranked higher than
79% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. ALIM: 5.85 )
Ranked among companies with meaningful Quick Ratio only.
ALIM' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 5.15 Max: 11.78
Current: 5.85
0.59
11.78
Days Inventory 135.25
ALIM's Days Inventory is ranked lower than
74% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. ALIM: 135.25 )
Ranked among companies with meaningful Days Inventory only.
ALIM' s Days Inventory Range Over the Past 10 Years
Min: 155.56  Med: 292.87 Max: 445.49
Current: 135.25
155.56
445.49
Days Sales Outstanding 111.82
ALIM's Days Sales Outstanding is ranked lower than
84% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. ALIM: 111.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALIM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.83  Med: 122.31 Max: 159.4
Current: 111.82
36.83
159.4
Days Payable 566.59
ALIM's Days Payable is ranked higher than
99% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. ALIM: 566.59 )
Ranked among companies with meaningful Days Payable only.
ALIM' s Days Payable Range Over the Past 10 Years
Min: 339.92  Med: 802.71 Max: 1270.92
Current: 566.59
339.92
1270.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -27.10
ALIM's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. ALIM: -27.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALIM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -175  Med: -6.25 Max: 0
Current: -27.1
-175
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.13
ALIM's Price-to-Median-PS-Value is ranked higher than
99% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. ALIM: 0.13 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALIM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 1 Max: 44.36
Current: 0.13
0.09
44.36
Earnings Yield (Greenblatt) % -14.45
ALIM's Earnings Yield (Greenblatt) % is ranked lower than
89% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. ALIM: -14.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALIM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -833.3  Med: 0 Max: 0
Current: -14.45
-833.3
0

More Statistics

Revenue (TTM) (Mil) $35.15
EPS (TTM) $ -0.48
Beta2.79
Short Percentage of Float1.93%
52-Week Range $1.02 - 2.40
Shares Outstanding (Mil)64.90

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 46 65
EPS ($) -0.22 0.10
EPS without NRI ($) -0.22 0.10
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ALIM

Headlines

Articles On GuruFocus.com
Alimera Sciences Reports First Quarter 2017 Financial Results May 08 2017 
Alimera Sciences to Report First Quarter 2017 Financial Results on May 8th, 2017 May 03 2017 
Alimera Sciences Announces Data From 27 ILUVIEN® Studies to Be Presented at 2017 ARVO May 01 2017 
Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain Mar 13 2017 
Alimera Sciences to Present at the 29th Annual ROTH Conference Mar 07 2017 
Alimera Sciences to Present at the 37th Annual Cowen Health Care Conference Mar 03 2017 
Alimera Sciences Inc. (ALIM) President and CEO C. Daniel Myers sells 45,523 Shares Mar 16 2011 
The Most Speculative Stocks on the Market: Harbinger, Kaching Kaching, Alimera Sciences, Star Scient Jul 29 2010 

More From Other Websites
Edited Transcript of ALIM earnings conference call or presentation 9-May-17 12:00pm GMT May 18 2017
Investor Network: ALIMERA SCIENCES INC to Host Earnings Call May 09 2017
Alimera Sciences reports 1Q loss May 08 2017
Alimera Sciences Reports First Quarter 2017 Financial Results May 08 2017
Alimera Sciences to Report First Quarter 2017 Financial Results on May 8th, 2017 May 03 2017
ETFs with exposure to Alimera Sciences, Inc. : May 1, 2017 May 01 2017
Alimera Sciences Announces Data From 27 ILUVIEN® Studies to Be Presented at 2017 ARVO May 01 2017
ETFs with exposure to Alimera Sciences, Inc. : April 7, 2017 Apr 07 2017
Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
Alimera Sciences, Inc. (ALIM) Looks Good: Stock Up 12.8% Mar 14 2017
Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain Mar 13 2017
Alimera Sciences to Present at the 29th Annual ROTH Conference Mar 07 2017
Alimera Sciences to Present at the 37th Annual Cowen Health Care Conference Mar 03 2017
Edited Transcript of ALIM earnings conference call or presentation 2-Mar-17 3:00pm GMT Mar 02 2017
Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results Mar 01 2017
Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in... Feb 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)